Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact

Citations to this article

Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity
Emilie Mamessier, … , Alessandro Moretta, Daniel Olive
Emilie Mamessier, … , Alessandro Moretta, Daniel Olive
Published August 15, 2011
Citation Information: J Clin Invest. 2011;121(9):3609-3622. https://doi.org/10.1172/JCI45816.
View: Text | PDF
Research Article Oncology Article has an altmetric score of 4

Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity

  • Text
  • PDF
Abstract

NK cells are a major component of the antitumor immune response and are involved in controlling tumor progression and metastases in animal models. Here, we show that dysfunction of these cells accompanies human breast tumor progression. We characterized human peripheral blood NK (p-NK) cells and malignant mammary tumor-infiltrating NK (Ti-NK) cells from patients with noninvasive and invasive breast cancers. NK cells isolated from the peripheral blood of healthy donors and normal breast tissue were used as controls. With disease progression, we found that expression of activating NK cell receptors (such as NKp30, NKG2D, DNAM-1, and CD16) decreased while expression of inhibitory receptors (such as NKG2A) increased and that this correlated with decreased NK cell function, most notably cytotoxicity. Importantly, Ti-NK cells had more pronounced impairment of their cytotoxic potential than p-NK cells. We also identified several stroma-derived factors, including TGF-β1, involved in tumor-induced reduction of normal NK cell function. Our data therefore show that breast tumor progression involves NK cell dysfunction and that breast tumors model their environment to evade NK cell antitumor immunity. This highlights the importance of developing future therapies able to restore NK cell cytotoxicity to limit/prevent tumor escape from antitumor immunity.

Authors

Emilie Mamessier, Aude Sylvain, Marie-Laure Thibult, Gilles Houvenaeghel, Jocelyne Jacquemier, Rémy Castellano, Anthony Gonçalves, Pascale André, François Romagné, Gilles Thibault, Patrice Viens, Daniel Birnbaum, François Bertucci, Alessandro Moretta, Daniel Olive

×

Total citations by year

Year: 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2009 Total
Citations: 15 27 27 38 33 36 34 25 25 20 26 14 14 11 1 346
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal. Not all publishers participate in CrossRef, so this information is not comprehensive. Additionally, data may not reflect the most current citations to this article, and the data may differ from citation information available from other sources (for example, Google Scholar, Web of Science, and Scopus).

Citations to this article (346)

Title and authors Publication Year
AXL: shapers of tumor progression and immunosuppressive microenvironments
Liu Y, Xu L, Dou Y, He Y
Molecular Cancer 2025
Early-Stage Luminal B-like Breast Cancer Exhibits a More Immunosuppressive Tumor Microenvironment than Luminal A-like Breast Cancer
Moura T, Caramelo O, Silva I, Silva S, Gonçalo M, Portilha MA, Moreira JN, Gil AM, Laranjeira P, Paiva A
Biomolecules 2025
Natural killer cells occupy unique spatial neighborhoods in HER2- and HER2+ human breast cancers
Ehlers FA, Blise KE, Betts CB, Sivagnanam S, Kooreman LF, Hwang ES, Bos GM, Wieten L, Coussens LM
Breast Cancer Research : BCR 2025
Efficacy Evaluation of “Enhanced” Natural Killers with CISH and B2M Knockouts on Viability and Metabolic Status of 3D Glioblastoma Spheroid Cells in Patients
Yuzhakova DV, Sachkova DA, Shirmanova MV, Shcheslavskiy VI, Mozherov AM, Dashinimaev EB, Baklaushev VP, Yusubalieva GM
Modern Technologies in Medicine 2025
A membrane lipid signature unravels the dynamic landscape of group 1 innate lymphoid cells across the health-disease continuum
Frey HC, Sun X, Oudeif F, Corona DL, He Z, Won T, Schultz TL, Carruthers VB, Laouar A, Laouar Y
iScience 2025
Unravelling the Connection Between Energy Metabolism and Immune Senescence/Exhaustion in Patients with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
Van Campenhout J, Buntinx Y, Xiong HY, Wyns A, Polli A, Nijs J, Aerts JL, Laeremans T, Hendrix J
Biomolecules 2025
Cross-Talk Between Cancer and Its Cellular Environment—A Role in Cancer Progression
Turlej E, Domaradzka A, Radzka J, Drulis-Fajdasz D, Kulbacka J, Gizak A
Cells 2025
Breast Cancer and Tumor Microenvironment: The Crucial Role of Immune Cells
Moura T, Laranjeira P, Caramelo O, Gil AM, Paiva A
Current Oncology 2025
Uncovering the heterogeneity of NK cells on the prognosis of HCC by integrating bulk and single-cell RNA-seq data
Li J, Liu Z, Zhang G, Yin X, Yuan X, Xie W, Ding X
Frontiers in Oncology 2025
Immunocytes in the tumor microenvironment: recent updates and interconnections
Yu J, Fu L, Wu R, Che L, Liu G, Ran Q, Xia Z, Liang X, Zhao G
Frontiers in Immunology 2025
Unraveling the breast cancer tumor microenvironment: crucial factors influencing natural killer cell function and therapeutic strategies
Li F, Gao C, Huang Y, Qiao Y, Xu H, Liu S, Wu H
International Journal of Biological Sciences 2025
The diversity of natural killer cell functional and phenotypic states in cancer.
Rishabh K, Matosevic S
Cancer metastasis reviews 2025
KLRG1 expression induces functional exhaustion of NK cells in colorectal cancer patients
Xu C, Cao K, Ma A, Zheng M, Xu Y, Tang L
Cancer Immunology, Immunotherapy : CII 2025
A novel NKG2A alpaca nanobody targeting immune checkpoint blockade for the treatment of malignant melanoma
Guo X, Guo C, Li D, Bai Y, Abbas M, Fan R, Zhao Y
Frontiers in Veterinary Science 2025
NKG2D triggering hampers DNAM-1-mediated signaling in human NK cells
Marangio C, Milito ND, Putro E, Carnevale A, Capuano C, Zingoni A, Cippitelli M, Santoni A, Paolini R, Molfetta R
Frontiers in Immunology 2025
NK cell-triggered CCL5/IFNγ-CXCL9/10 axis underlies the clinical efficacy of neoadjuvant anti-HER2 antibodies in breast cancer
Santana-Hernández S, Suarez-Olmos J, Servitja S, Berenguer-Molins P, Costa-Garcia M, Comerma L, Rea A, Perera-Bel J, Menendez S, Arpí O, Bermejo B, Martínez MT, Cejalvo JM, Comino-Méndez I, Pascual J, Alba E, López-Botet M, Rojo F, Rovira A, Albanell J, Muntasell A
Journal of experimental & clinical cancer research : CR 2024
Expression analysis of lymphocyte subsets and lymphocyte-to-monocyte ratio: reveling immunosuppression and chronic inflammation in breast cancer
Zhang H, Li Y, Liu G, Chen X
Journal of Cancer Research and Clinical Oncology 2024
Phase 1/2 study of monalizumab plus durvalumab in patients with advanced solid tumors.
Patel SP, Alonso-Gordoa T, Banerjee S, Wang D, Naidoo J, Standifer NE, Palmer DC, Cheng LY, Kourtesis P, Ascierto ML, Das M, Diamond JR, Hellmann MD, Carneiro BA
Journal for ImmunoTherapy of Cancer 2024
Cellular interactions in tumor microenvironment during breast cancer progression: new frontiers and implications for novel therapeutics
Akinsipe T, Mohamedelhassan R, Akinpelu A, Pondugula SR, Mistriotis P, Avila LA, Suryawanshi A
Frontiers in immunology 2024
Targeting Pivotal Hallmarks of Cancer for Enhanced Therapeutic Strategies in Triple-Negative Breast Cancer Treatment—In Vitro, In Vivo and Clinical Trials Literature Review
Szulc A, Woźniak M
Cancers 2024
Interleukin-2 is required for NKp30-dependent NK cell cytotoxicity by preferentially regulating NKp30 expression
Kim N, Yi E, Lee E, Park HJ, Kim HS
Frontiers in immunology 2024
No time to die: Epigenetic regulation of natural killer cell survival.
Hermans L, O'Sullivan TE
Immunological Reviews 2024
Predictive value of lymphocyte subsets and lymphocyte-to-monocyte ratio in assessing the efficacy of neoadjuvant therapy in breast cancer
Zhang H, Li Y, Liu YW, Liu YG, Chen X
Scientific Reports 2024
BCG priming followed by a novel interleukin combination activates Natural Killer cells to selectively proliferate and become anti-tumour long-lived effectors
Felgueres MJ, Esteso G, García-Jiménez ÁF, Dopazo A, Aguiló N, Mestre-Durán C, Martínez-Piñeiro L, Pérez-Martínez A, Reyburn HT, Valés-Gómez M
Scientific Reports 2024
Natural killer cells in cancer immunotherapy
Wang D, Dou L, Sui L, Xue Y, Xu S
MedComm 2024
Modulation of blood T cell polyfunctionality and HVEM/BTLA expression are critical determinants of clinical outcome in anti-PD1-treated metastatic melanoma patients
Dalle S, Verronese E, N\u2019Kodia A, Bardin C, Rodriguez C, Andrieu T, Eberhardt A, Chemin G, Hasan U, Le-Bouar M, Caramel J, Amini-Adle M, Bendriss-Vermare N, Dubois B, Caux C, Ménétrier-Caux C
OncoImmunology 2024
High-dimensional mapping of human CEACAM1 expression on immune cells and association with melanoma drug resistance
Huang YH, Yoon CH, Gandhi A, Hanley T, Castrillon C, Kondo Y, Lin X, Kim W, Yang C, Driouchi A, Carroll M, Gray-Owen SD, Wesemann DR, Drake CG, Bertagnolli MM, Beauchemin N, Blumberg RS
2024
IFNγ mediates the resistance of tumor cells to distinct NK cell subsets
Hofman T, Ng SW, Garcés-Lázaro I, Heigwer F, Boutros M, Cerwenka A
Journal for ImmunoTherapy of Cancer 2024
Human NK cells and cancer
Cantoni C, Falco M, Vitale M, Pietra G, Munari E, Pende D, Mingari MC, Sivori S, Moretta L
OncoImmunology 2024
Accumulation of CD56+ CD16- Natural Killer Cells in Response to Preoperative Chemotherapy for Breast Cancer
Kim R, Kawai A, Wakisaka M, Shimoyama M, Yasuda N, Ito M, Kin T, Arihiro K
World Journal of Oncology 2024
Natural Killer-Based Therapy: A Prospective Thought for Cancer Treatment Related to Diversified Drug Delivery Pathways
Zang J, Mei Y, Zhu S, Yin S, Feng N, Ci T, Lyu Y
Pharmaceutics 2024
Progress on immuno-microenvironment and immune-related therapies in patients with pseudomyxoma peritonei
Zhao Q, Wei T, Ma R, Fu Y, Yang R, Su Y, Yu Y, Li B, Li Y
Cancer biology & medicine 2024
HPK1 Dysregulation‐Associated NK Cell Dysfunction and Defective Expansion Promotes Metastatic Melanoma Progression
Choi WS, Kwon H, Yi E, Lee H, Kim JM, Park HJ, Choi EJ, Choi ME, Sung YH, Won CH, Sung CO, Kim HS
Advanced Science 2024
Natural Killer cells at the frontline in the fight against cancer
Coënon L, Geindreau M, Ghiringhelli F, Villalba M, Bruchard M
Cell Death & Disease 2024
CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors
Peng L, Sferruzza G, Yang L, Zhou L, Chen S
Cellular and Molecular Immunology 2024
Intracellular checkpoints for NK cell cancer immunotherapy.
Huang Y, Tian Z, Bi J
Frontiers of medicine 2024
STYK1 mediates NK cell anti-tumor response through regulating CCR2 and trafficking
He J, He Y, Biao R, Wei Y, Dong Z, Du J
Journal of Translational Medicine 2024
Unlocking the therapeutic potential of the NKG2A-HLA-E immune checkpoint pathway in T cells and NK cells for cancer immunotherapy.
Li Y, Li Z, Tang Y, Zhuang X, Feng W, Boor PPC, Buschow S, Sprengers D, Zhou G
Journal for immunotherapy of cancer 2024
Comprehensive snapshots of natural killer cells functions, signaling, molecular mechanisms and clinical utilization
Chen S, Zhu H, Jounaidi Y
Signal Transduction and Targeted Therapy 2024
Metabolic reprogramming and therapeutic resistance in primary and metastatic breast cancer.
Liu S, Zhang X, Wang W, Li X, Sun X, Zhao Y, Wang Q, Li Y, Hu F, Ren H
Molecular cancer 2024
CBL0137 and NKG2A blockade: a novel immuno-oncology combination therapy for Myc-overexpressing triple-negative breast cancers
Raninga PV, Zeng B, Moi D, Trethowan E, Saletta F, Venkat P, Mayoh C, D\u2019Souza RC, Day BW, Shai-Hee T, Vittorio O, Mazzieri R, Dolcetti R, Khanna KK
Oncogene 2024
Targeting metabolic dysfunction of CD8 T cells and natural killer cells in cancer.
Viel S, Vivier E, Walzer T, Marçais A
Nature reviews. Drug discovery 2024
Alteration of the NKG2A on NK cells and ligands on exosomes in the peripheral blood after prostatectomy are key regulators of natural killer cell activity
Yu-Chuan Lu, Chen-Hsun Ho, Jian-Hua Hong, Ming-Chieh Kuo, Fu-Shan Jaw, Jason Chia-Hsien Cheng, Chao-Yuan Huang, Koping Chang, Jung-An Lin, Hsiu-Ni Kung
Molecular Oncology 2023
The inhibitory NKR-P1B receptor regulates NK cell-mediated mammary tumor immunosurveillance in mice
Al Olabi R, Hendy AE, Alkassab MB, Alnajm K, Elias M, Ibrahim M, Carlyle JR, Makrigiannis AP, Rahim MM
OncoImmunology 2023
Neoadjuvant chemotherapy modulates exhaustion of T cells in breast cancer patients
Rodríguez IJ, Bernal-Estévez DA, Llano-León M, Bonilla CE, Parra-López CA
PloS one 2023
Status and prognostic value of immunological biomarkers of breast cancer
Murazawa C, Hashimoto N, Kuraishi K, Motoyama M, Hashimoto SI, Ikeuchi M, Norimura S, Matsunaga T, Teramoto K, Haba R, Abe N, Yajima T, Kontani K
Oncology Letters 2023
Addressing Natural Killer Cell Dysfunction and Plasticity in Cell-Based Cancer Therapeutics
Coyle KM, Hawke LG, Ormiston ML
Cancers 2023
Emerging Targeted Therapies for HER2-Positive Breast Cancer
Mercogliano MF, Bruni S, Mauro FL, Schillaci R
Cancers 2023
The Function of NK Cells in Tumor Metastasis and NK Cell-Based Immunotherapy
Yu Y
Cancers 2023
Transforming growth factor-β signaling: from tumor microenvironment to anticancer therapy
Chan MK, Chan EL, Ji ZZ, Chan AS, Li C, Leung KT, To KF, Tang PM
2023
Harnessing the power of memory-like NK cells to fight cancer
Foo YY, Tiah A, Aung SW
Clinical & Experimental Immunology 2023
TMEM147 Correlates with Immune Infiltration and Serve as a Potential Prognostic Biomarker in Hepatocellular Carcinoma
Cheng S, Li J, Xu M, Bao Q, Wu J, Sun P, Han B
Analytical cellular pathology (Amsterdam) 2023
The NK cell checkpoint NKG2A maintains expansion capacity of human NK cells
Kaulfuss M, Mietz J, Fabri A, vom Berg J, Münz C, Chijioke O
Scientific Reports 2023
Comprehensive analysis of angiogenesis pattern and related immune landscape for individual treatment in osteosarcoma.
Liao Z, Li M, Wen G, Wang K, Yao D, Chen E, Liang Y, Xing T, Su K, Liang C, Che Z, Ning Q, Tang J, Yan W, Li Y, Huang L
npj Precision Oncology 2023
Immune evasion and therapeutic opportunities based on natural killer cells
Zhang J, Guo F, Li L, Zhang S, Wang Y
Chinese Journal of Cancer Research 2023
Natural killer cell-related prognostic risk model predicts prognosis and treatment outcomes in triple-negative breast cancer
Liu Z, Ding M, Qiu P, Pan K, Guo Q
Frontiers in immunology 2023
Circulating natural killer cells and their association with breast cancer and its clinico-pathological characteristics
Marcelin HN, Dasse RS, Yeboah RO, Tariam AD, Kagambega AG, Oseni AM, Kouassi YK, Bilé MA, Toure M, Thakar M, Adoubi I, Kizub D
ecancermedicalscience 2023
Understanding NK cell biology for harnessing NK cell therapies: targeting cancer and beyond
Shin E, Bak SH, Park T, Kim JW, Yoon SR, Jung H, Noh JY
Frontiers in immunology 2023
Natural Killer Cell Engagers (NKCEs): a new frontier in cancer immunotherapy.
Zhang M, Lam KP, Xu S
Frontiers in immunology 2023
Combining bulk and single-cell RNA-sequencing data to develop an NK cell-related prognostic signature for hepatocellular carcinoma based on an integrated machine learning framework
Feng Q, Huang Z, Song L, Wang L, Lu H, Wu L
European Journal of Medical Research 2023
Dysregulation of DNAM-1-Mediated NK Cell Anti-Cancer Responses in the Tumor Microenvironment
Paolini R, Molfetta R
Cancers 2023
Perspectives of targeting LILRB1 in innate and adaptive immune checkpoint therapy of cancer
Zeller T, Münnich IA, Windisch R, Hilger P, Schewe DM, Humpe A, Kellner C
Frontiers in immunology 2023
B-cells and regulatory T-cells in the microenvironment of HER2+ breast cancer are associated with decreased survival: a real-world analysis of women with HER2+ metastatic breast cancer
Steenbruggen TG, Wolf DM, Campbell MJ, Sanders J, Cornelissen S, Thijssen B, Salgado RA, Yau C, O-Grady N, Basu A, Bhaskaran R, Mittempergher L, Hirst GL, Coppe JP, Kok M, Sonke GS, van \u2018t Veer LJ, Horlings HM
Breast Cancer Research 2023
Highly expressed RPLP2 inhibits ferroptosis to promote hepatocellular carcinoma progression and predicts poor prognosis
Guo J, Huang M, Deng S, Wang H, Wang Z, Yan B
Cancer Cell International 2023
Evaluation of circulating plasma proteins in breast cancer using Mendelian randomisation
Mälarstig A, Grassmann F, Dahl L, Dimitriou M, McLeod D, Gabrielson M, Smith-Byrne K, Thomas CE, Huang TH, Forsberg SK, Eriksson P, Ulfstedt M, Johansson M, Sokolov AV, Schiöth HB, Hall P, Schwenk JM, Czene K, Hedman ÅK
Nature Communications 2023
Non-coding RNA-Mediated N6-Methyladenosine (m6A) deposition: A pivotal regulator of cancer, impacting key signaling pathways in carcinogenesis and therapy response
Hashemi M, Daneii P, Zandieh MA, Raesi R, Zahmatkesh N, Bayat M, Abuelrub A, Khazaei Koohpar Z, Aref AR, Zarrabi A, Rashidi M, Salimimoghadam S, Entezari M, Taheriazam A, Khorrami R
Non-coding RNA Research 2023
The Role of NKG2D and Its Ligands in Autoimmune Diseases: New Targets for Immunotherapy
Wei L, Xiang Z, Zou Y
International journal of molecular sciences 2023
Strategies to overcome low MHC-I expression in paediatric and adult tumours
Guillaume J, Perzolli A, Boes M
2023
Fat Biology in Triple-Negative Breast Cancer: Immune Regulation, Fibrosis, and Senescence
Lee CM, Fang S
Journal of Obesity & Metabolic Syndrome 2023
Balanced engagement of activating and inhibitory receptors mitigates human NK cell exhaustion
Jacob A Myers, Dawn Schirm, Laura Bendzick, Rachel Hopps, Carly Selleck, Peter Hinderlie, Martin Felices, Jeffrey Miller
JCI Insight 2022
Breast Cancer Tumor Microenvironment and Molecular Aberrations Hijack Tumoricidal Immunity
H Lin, Y Liu, D Lofland, J Lin
Cancers 2022
B cells and tertiary lymphoid structures as determinants of tumour immune contexture and clinical outcome
W Fridman, M Meylan, F Petitprez, C Sun, A Italiano, C Sautès-Fridman
Nature Reviews Clinical Oncology 2022
Tumor Microenvironment and Hydrogel-Based 3D Cancer Models for In Vitro Testing Immunotherapies
C Vitale, M Marzagalli, S Scaglione, A Dondero, C Bottino, R Castriconi
Cancers 2022
Back to the Future: Spatiotemporal Determinants of NK Cell Antitumor Function
J Li, T OSullivan
Frontiers in immunology 2022
Innate lymphoid cells: NK and cytotoxic ILC3 subsets infiltrate metastatic breast cancer lymph nodes
L Rethacker, M Boy, V Bisio, F Roussin, J Denizeau, A Vincent-Salomon, E Borcoman, C Sedlik, E Piaggio, A Toubert, N Dulphy, A Caignard
OncoImmunology 2022
Innate Immunity and Cancer Pathophysiology
L Maiorino, J Daßler-Plenker, L Sun, M Egeblad
Annual review of pathology 2022
Harnessing natural killer cells for cancer immunotherapy: dispatching the first responders
N Maskalenko, D Zhigarev, K Campbell
Nature Reviews Drug Discovery 2022
Role of the ITAM-Bearing Receptors Expressed by Natural Killer Cells in Cancer
Medjouel Khlifi H, Guia S, Vivier E, Narni-Mancinelli E
Frontiers in immunology 2022
Cytotoxic innate lymphoid cells sense cancer cell-expressed interleukin-15 to suppress human and murine malignancies.
Kansler ER, Dadi S, Krishna C, Nixon BG, Stamatiades EG, Liu M, Kuo F, Zhang J, Zhang X, Capistrano K, Blum KA, Weiss K, Kedl RM, Cui G, Ikuta K, Chan TA, Leslie CS, Hakimi AA, Li MO
Nature Immunology 2022
NCAPG Promotes Tumor Progression and Modulates Immune Cell Infiltration in Glioma
Zheng G, Han T, Hu X, Yang Z, Wang J, Wen Z, Li H, Wang H
Frontiers in Oncology 2022
Plasticity of NK cells in Cancer
Corvino D, Kumar A, Bald T
Frontiers in immunology 2022
Tissue-Resident Innate Immune Cell-Based Therapy: A Cornerstone of Immunotherapy Strategies for Cancer Treatment
Busà R, Bulati M, Badami E, Zito G, Maresca DC, Conaldi PG, Ercolano G, Ianaro A
Frontiers in Cell and Developmental Biology 2022
Immunotherapeutic targeting of activating natural killer cell receptors and their ligands in cancer
Peipp M, Klausz K, Boje AS, Zeller T, Zielonka S, Kellner C
Clinical & Experimental Immunology 2022
The Significance of MicroRNAs in the Molecular Pathology of Brain Metastases
Siegl F, Vecera M, Roskova I, Smrcka M, Jancalek R, Kazda T, Slaby O, Sana J
Cancers 2022
Potential of chimeric antigen receptor (CAR)‐redirected immune cells in breast cancer therapies: Recent advances
Nikoo M, Rudiansyah M, Bokov DO, Jainakbaev NT, Suksatan W, Ansari MJ, Thangavelu L, Chupradit S, Zamani A, Adili A, Shomali N, Akbari M
Journal of Cellular and Molecular Medicine 2022
NK cell dysfunction is linked with disease severity in SARS‐CoV‐2 patients
Dizaji Asl K, Mazloumi Z, Majidi G, Kalarestaghi H, Sabetkam S, Rafat A
Cell Biochemistry and Function 2022
Immunotherapy and immunoengineering for breast cancer; a comprehensive insight into CAR-T cell therapy advancements, challenges and prospects.
Bozorgi A, Bozorgi M, Khazaei M
Cellular oncology (Dordrecht) 2022
Peripheral blood lymphocytes subtypes as new predictors for neoadjuvant therapy efficacy in breast cancer
Feng J, Yi J, Zouxu X, Li J, Xiong Z, Huang X, Zhong W, Huang W, Ye F, Wang X
Cancer Medicine 2022
Hallmarks of Cancer Applied to Oral and Oropharyngeal Carcinogenesis: A Scoping Review of the Evidence Gaps Found in Published Systematic Reviews
González-Moles MÁ, Warnakulasuriya S, López-Ansio M, Ramos-García P
Cancers 2022
The role of the natural killer (NK) cell modulation in breast cancer incidence and progress.
Razeghian E, Kameh MC, Shafiee S, Khalafi F, Jafari F, Asghari M, Kazemi K, Ilkhani S, Shariatzadeh S, Haj-Mirzaian A
Molecular Biology Reports 2022
Underlying mechanisms of evasion from NK cells as rationale for improvement of NK cell-based immunotherapies
Seliger B, Koehl U
Frontiers in immunology 2022
Compromised activity of natural killer cells in diffuse large b-cell lymphoma is related to lymphoma-induced modification of their surface receptor expression.
Azoulay T, Slouzky I, Karmona M, Filatov M, Hayun M, Ofran Y, Sarig G, Ringelstein-Harlev S
Cancer Immunology, Immunotherapy 2022
NKG2A-checkpoint inhibition and its blockade critically depends on peptides presented by its ligand HLA-E.
Battin C, Kaufmann G, Leitner J, Tobias J, Wiedermann U, Rölle A, Meyer M, Momburg F, Steinberger P
Immunology 2022
BND-22, a first-in-class humanized ILT2-blocking antibody, promotes antitumor immunity and tumor regression
Mandel I, Haves Ziv D, Goldshtein I, Peretz T, Alishekevitz D, Fridman Dror A, Hakim M, Hashmueli S, Friedman I, Sapir Y, Greco R, Qu H, Nestle F, Wiederschain D, Pao L, Sharma S, Ben Moshe T
Journal for ImmunoTherapy of Cancer 2022
N-cadherin protects oral cancer cells from NK cell killing in the circulation by inducing NK cell functional exhaustion via the KLRG1 receptor
Lou C, Wu K, Shi J, Dai Z, Xu Q
Journal for ImmunoTherapy of Cancer 2022
TEM8 Tri-specific Killer Engager binds both tumor and tumor stroma to specifically engage natural killer cell anti-tumor activity
Kaminski MF, Bendzick L, Hopps R, Kauffman M, Kodal B, Soignier Y, Hinderlie P, Walker JT, Lenvik TR, Geller MA, Miller JS, Felices M
Journal for ImmunoTherapy of Cancer 2022
TIMM8A is associated with dysfunction of immune cell in BRCA and UCEC for predicting anti-PD-L1 therapy efficacy
Zhu X, Yuan Z, Cheng S, Wang H, Liao Y, Zhou D, Wu Z
World journal of surgical oncology 2022
The Next Generation of Cellular Immunotherapy: CAR-NK Cells
Moscarelli J, Zahavi D, Maynard R, Weiner L
2022
The soldiers needed to be awakened: Tumor-infiltrating immune cells
Yaping W, Zhe W, Zhuling C, Ruolei L, Pengyu F, Lili G, Cheng J, Bo Z, Liuyin L, Guangdong H, Yaoling W, Niuniu H, Rui L
Frontiers in Genetics 2022
Next Generation Immuno-Oncology Strategies: Unleashing NK Cells Activity
Mendoza-Valderrey A, Alvarez M, De Maria A, Margolin K, Melero I, Ascierto ML
Cells 2022
SARS-CoV-2 Infection: A Possible Risk Factor for Incidence and Recurrence of Cancers.
Jafarzadeh A, Gosain R, Mortazavi SMJ, Nemati M, Jafarzadeh S, Ghaderi A
International journal of hematology-oncology and stem cell research 2022
DNA barcoding reveals ongoing immunoediting of clonal cancer populations during metastatic progression and immunotherapy response.
Baldwin LA, Bartonicek N, Yang J, Wu SZ, Deng N, Roden DL, Chan CL, Al-Eryani G, Zanker DJ, Parker BS, Swarbrick A, Junankar S
Nature Communications 2022
Protective Effect of the Polysaccharides from Taraxacum mongolicum Leaf by Modulating the p53 Signaling Pathway in H22 Tumor-Bearing Mice
Chen P, Chen Y, Yan ZQ, Ding SY, Liu HP, Tu JQ, Zhang XW
Foods 2022
Suppression of CD56(bright) NK cells in breast cancer patients is associated with the PD-1 and TGF-βRII expression.
Arianfar E, Khandoozi SR, Mohammadi S, Memarian A
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2022
Natural Killer Cells: A Promising Kit in the Adoptive Cell Therapy Toolbox
Xiao J, Zhang T, Gao F, Zhou Z, Shu G, Zou Y, Yin G
Cancers 2022
Harnessing NK Cells to Control Metastasis.
Deng X, Terunuma H
Human vaccines 2022
Mass cytometry-based peripheral blood analysis as a novel tool for early detection of solid tumours: a multicentre study.
Zhang Q, Ye M, Lin C, Hu M, Wang Y, Lou Y, Kong Q, Zhang J, Li J, Zhang Y, Yang T, Sun X, Yao W, Hua Y, Huang H, Xu M, Wang X, Yu X, Tao W, Liu R, Gao Y, Wang T, Wang J, Wei X, Wu J, Yu Z, Zhang C, Yu C, Bai X, Liang T
Gut 2022
TGFβ drives NK cell metabolic dysfunction in human metastatic breast cancer
K Slattery, E Woods, V Zaiatz-Bittencourt, S Marks, S Chew, M Conroy, C Goggin, C MacEochagain, J Kennedy, S Lucas, DK Finlay, CM Gardiner
Journal for ImmunoTherapy of Cancer 2021
NK and NKT cells have distinct properties and functions in cancer
X Liu, L Li, F Si, L Huang, Y Zhao, C Zhang, DF Hoft, G Peng
Oncogene 2021
Natural Killer Cells: The Linchpin for Successful Cancer Immunotherapy
KA Shaver, TJ Croom-Perez, AJ Copik
Frontiers in immunology 2021
MHC Class I Deficiency in Solid Tumors and Therapeutic Strategies to Overcome It
E Shklovskaya, H Rizos
International journal of molecular sciences 2021
Overcoming TGFβ-mediated immune evasion in cancer
DV Tauriello, E Sancho, E Batlle
Nature Reviews Cancer 2021
The Role of NK Cells in EBV Infection and EBV-Associated NPC
YT Png, AZ Yang, MY Lee, MJ Chua, CM Lim
Viruses 2021
Lipid Metabolism in Tumor Immunity
Y Li
2021
The Interplay of Exosomes and NK Cells in Cancer Biology
IA Batista, ST Quintas, SA Melo
Cancers 2021
Targeting the purinergic pathway in breast cancer and its therapeutic applications
JB de Araújo, VV Kerkhoff, SF de Oliveira Maciel, DT de Resende e Silva
Purinergic Signalling 2021
Arrested development: suppression of NK cell function in the tumor microenvironment
L Riggan, S Shah, TE OSullivan
IBMS BoneKEy 2021
Preliminary results from whole-genome expression analysis in patients with secondary adrenal insufficiency treated with modified-release hydrocortisone
T Pilli, S Cardinale, S Cantara, G Dalmazio, R Forleo, M Capezzone, C Bassi, M Negrini, M Ferracin, MG Castagna
Endocrine 2021
Leukocyte immunoglobulin-like receptor subfamily B: therapeutic targets in cancer
M Deng, H Chen, X Liu, R Huang, Y He, B Yoo, J Xie, S John, N Zhang, Z An, CC Zhang
2021
The Peripheral Immune Landscape of Breast Cancer: Clinical Findings and In Vitro Models for Biomarker Discovery
S Batalha, S Ferreira, C Brito
Cancers 2021
Tackling tumor microenvironment through epigenetic tools to improve cancer immunotherapy
I Lodewijk, SP Nunes, R Henrique, C Jerónimo, M Dueñas, JM Paramio
Clinical Epigenetics 2021
Systemic immunity in cancer
KJ Hiam-Galvez, BM Allen, MH Spitzer
Nature Reviews Cancer 2021
Natural Killer Cell Subpopulations and Inhibitory Receptor Dynamics in Myelodysplastic Syndromes and Acute Myeloid Leukemia
VA Cianga, LC Catafal, P Cianga, MP Tanasa, M Cherry, P Collet, E Tavernier, D Guyotat, C Rusu, CM Aanei
Frontiers in immunology 2021
Natural Killer Cell Interactions With Myeloid Derived Suppressor Cells in the Tumor Microenvironment and Implications for Cancer Immunotherapy
C Zalfa, S Paust
Frontiers in immunology 2021
High expression of COMMD7 is an adverse prognostic factor in acute myeloid leukemia
K Li, L Chen, H Zhang, L Wang, K Sha, X Du, D Li, Z Zheng, R Pei, Y Lu, H Tong
Aging 2021
Immune System Effects on Breast Cancer
JN Amens, G Bahçecioglu, P Zorlutuna
Cellular and Molecular Bioengineering 2021
Angiogenic Properties of NK Cells in Cancer and Other Angiogenesis-Dependent Diseases
DM Radomska-Leśniewska, A Białoszewska, P Kamiński
Cells 2021
Immune Circuits to Shape Natural Killer Cells in Cancer
I Mattiola
Cancers 2021
Transcription factor Zhx2 restricts NK cell maturation and suppresses their antitumor immunity
S Tan, X Guo, M Li, T Wang, Z Wang, C Li, Z Wu, N Li, L Gao, X Liang, C Ma
Journal of Experimental Medicine 2021
Dynamic switch of immunity and antitumor effects of metformin in rat spontaneous esophageal carcinogenesis
R Takei, T Miyashita, S Takada, H Tajima, I Ninomiya, H Takamura, S Fushida, A Harashima, S Munesue, S Yagi, N Inaki, T Ohta, Y Yamamoto
Cancer Immunology, Immunotherapy 2021
The Dual Role of Innate Lymphoid and Natural Killer Cells in Cancer. from Phenotype to Single-Cell Transcriptomics, Functions and Clinical Uses
S Roma, L Carpen, A Raveane, F Bertolini
Cancers 2021
Exhausted NK cells and cytokine storms in COVID-19: Whether NK cell therapy could be a therapeutic choice
M Ghasemzadeh, A Ghasemzadeh, E Hosseini
Human Immunology 2021
Combining AFM13, a Bispecific CD30/CD16 Antibody, with Cytokine-Activated Blood and Cord Blood–Derived NK Cells Facilitates CAR-like Responses Against CD30 + Malignancies
LN Kerbauy, ND Marin, M Kaplan, PP Banerjee, MM Berrien-Elliott, M Becker-Hapak, R Basar, M Foster, LG Melo, CC Neal, E McClain, M Daher, AK Cortes, S Desai, FW Lim, MC Mendt, T Schappe, L Li, H Shaim, M Shanley, EL Ensley, N Uprety, P Wong, E Liu, SO Ang, R Cai, V Nandivada, V Mohanty, Q Miao, Y Shen, N Baran, NW Fowlkes, K Chen, L Muniz-Feliciano, RE Champlin, YL Nieto, J Koch, M Treder, W Fischer, OK Okamoto, EJ Shpall, TA Fehniger, K Rezvani
Clinical cancer research 2021
NK Cells in a Tug-of-War With Cancer: The Roles of Transcription Factors and Cytoskeleton
EH Lee, DC Wong, JL Ding
Frontiers in immunology 2021
TIGIT + TIM-3 + NK cells are correlated with NK cell exhaustion and disease progression in patients with hepatitis B virus‑related hepatocellular carcinoma
L Yu, X Liu, X Wang, F Yan, P Wang, Y Jiang, J Du, Z Yang
OncoImmunology 2021
CAR‐NK cell in cancer immunotherapy; A promising frontier
F Marofi, OF AbdulRasheed, HS Rahman, HS Budi, AT Jalil, AV Yumashev, A Hassanzadeh, M Yazdanifar, R Motavalli, MS Chartrand, M Ahmadi, A CidArreguid, M Jarahian
Cancer Science 2021
Epigenetic quantification of circulating immune cells in peripheral blood of triple-negative breast cancer patients
M Manoochehri, T Hielscher, N Borhani, C Gerhäuser, O Fletcher, AJ Swerdlow, YD Ko, H Brauch, T Brüning, U Hamann
Clinical Epigenetics 2021
Neoadjuvant STING Activation, Extended Half-life IL2, and Checkpoint Blockade Promote Metastasis Clearance via Sustained NK-cell Activation
L Milling, D Garafola, Y Agarwal, S Wu, A Thomas, N Donahue, J Adams, N Thai, H Suh, D Irvine
Cancer immunology research 2021
Neutrophil and Natural Killer Cell Interactions in Cancers: Dangerous Liaisons Instructing Immunosuppression and Angiogenesis
MT Palano, M Gallazzi, M Cucchiara, AD Barbaro, D Gallo, B Bassani, A Bruno, L Mortara
Human vaccines 2021
C3aR Signaling Inhibits NK-cell Infiltration into the Tumor Microenvironment in Mouse Models
Nandagopal S, Li CG, Xu Y, Sodji QH, Graves EE, Giaccia AJ
Cancer immunology research 2021
IL15 Stimulation with TIGIT Blockade Reverses CD155-mediated NK-Cell Dysfunction in Melanoma
JM Chauvin, M Ka, O Pagliano, C Menna, Q Ding, R DeBlasio, C Sanders, J Hou, XY Li, S Ferrone, D Davar, JM Kirkwood, RJ Johnston, AJ Korman, MJ Smyth, HM Zarour
Clinical cancer research 2020
Harnessing NK Cell Checkpoint-Modulating Immunotherapies
SK Chauhan, U Koehl, S Kloess
Cancers 2020
Targeting novel inhibitory receptors in cancer immunotherapy
QQ Ding, JM Chauvin, HM Zarour
Seminars in Immunology 2020
Inflammasome Deletion Promotes Anti-tumor NK Cell Function in an IL-1/IL-18 Independent Way in Murine Invasive Breast Cancer
B Guey, M Bodnar-Wachtel, A Drouillard, A Eberhardt, M Pratviel, N Goutagny, N Bendriss-Vermare, I Puisieux, C Caux, T Walzer, V Petrilli
Frontiers in Oncology 2020
Unleashing Natural Killer Cells in the Tumor Microenvironment–The Next Generation of Immunotherapy?
A Ben-Shmuel, G Biber, M Barda-Saad
Frontiers in immunology 2020
NK cells for cancer immunotherapy
N Shimasaki, A Jain, D Campana
Nature Reviews Drug Discovery 2020
Genetic Engineering of Natural Killer Cells for Enhanced Antitumor Function
S Mantesso, D Geerts, J Spanholtz, L Kučerová
Frontiers in immunology 2020
Mechanisms of Resistance to NK Cell Immunotherapy
C Sordo-Bahamonde, M Vitale, S Lorenzo-Herrero, A López-Soto, S Gonzalez
Cancers 2020
Hitting More Birds with a Stone: Impact of TGF-β on ILC Activity in Cancer
C Fionda, H Stabile, C Cerboni, A Soriani, A Gismondi, M Cippitelli, A Santoni
Journal of Clinical Medicine 2020
The Immune Checkpoint PD-1 in Natural Killer Cells: Expression, Function and Targeting in Tumour Immunotherapy
L Quatrini, FR Mariotti, E Munari, N Tumino, P Vacca, L Moretta
Cancers 2020
Dichotomous Regulation of Acquired Immunity by Innate Lymphoid Cells
T Ebihara
Cells 2020
The Multifaceted Nature of Tumor Microenvironment in Breast Carcinomas
L Annaratone, E Cascardi, E Vissio, I Sarotto, E Chmielik, A Sapino, E Berrino, C Marchiò
Pathobiology 2020
The Tumor Microenvironment—A Metabolic Obstacle to NK Cells’ Activity
J Domagala, M Lachota, M Klopotowska, A Graczyk-Jarzynka, A Domagala, A Zhylko, K Soroczynska, M Winiarska
Cancers 2020
Tissue factor as a new target for CAR-NK cell immunotherapy of triple-negative breast cancer
Z Hu
Scientific Reports 2020
Overview of Strategies to Improve Therapy against Tumors Using Natural Killer Cell
C Yang, Y Li, Y Yang, Z Chen
Journal of Immunology Research 2020
Modeling chemical effects on breast cancer: the importance of the microenvironment in vitro
MM Morgan, LA Schuler, JC Ciciliano, BP Johnson, ET Alarid, DJ Beebe
Integrative biology : quantitative biosciences from nano to macro 2020
NK and NKT Cell-Mediated Immune Surveillance against Hematological Malignancies
K Shimizu, T Iyoda, S Yamasaki, N Kadowaki, A Tojo, S Fujii
Cancers 2020
Innate immunity in COVID-19 patients mediated by NKG2A receptors, and potential treatment using Monalizumab, Cholroquine, and antiviral agents
A Yaqinuddin, J Kashir
Medical Hypotheses 2020
PD-1+ natural killer cells in human non-small cell lung cancer can be activated by PD-1/PD-L1 blockade
MP Trefny, M Kaiser, MA Stanczak, P Herzig, S Savic, M Wiese, D Lardinois, H Läubli, F Uhlenbrock, A Zippelius
Cancer Immunology, Immunotherapy 2020
Renal cell tumors convert natural killer cells to a proangiogenic phenotype
Y Guan, CB Chambers, T Tabatabai, H Hatley, KR Delfino, K Robinson, SR Alanee, S Ran, DS Torry, A Wilber
Oncotarget 2020
IL-6-induced CD39 expression on tumor-infiltrating NK cells predicts poor prognosis in esophageal squamous cell carcinoma
Y Zheng, Y Li, B Tang, Q Zhao, D Wang, Y Liu, M Guo, S Zhao, Y Qi, Y Zhang, L Huang
Cancer Immunology, Immunotherapy 2020
miRNAs in Health and Disease: A Focus on the Breast Cancer Metastatic Cascade towards the Brain
M Sereno, M Videira, I Wilhelm, IA Krizbai, MA Brito
Cells 2020
Antagonistic anti-LILRB1 monoclonal antibody regulates antitumor functions of natural killer cells
H Chen, Y Chen, M Deng, S John, X Gui, A Kansagra, W Chen, J Kim, C Lewis, G Wu, J Xie, L Zhang, R Huang, X Liu, H Arase, Y Huang, H Yu, W Luo, N Xia, N Zhang, Z An, CC Zhang
Journal for ImmunoTherapy of Cancer 2020
NK cells beat T cells at early breast cancer control
A Buque, N Bloy, G Petroni, G Kroemer, L Galluzzi
OncoImmunology 2020
Immune microenvironment in different molecular subtypes of ductal breast carcinoma
M Sadeghalvad, HR Mohammadi-Motlagh, N Rezaei
Breast Cancer Research and Treatment 2020
Natural killer cells in the human lung tumor microenvironment display immune inhibitory functions
J Russick, PE Joubert, M Gillard-Bocquet, C Torset, M Meylan, F Petitprez, MA Dragon-Durey, S Marmier, A Varthaman, N Josseaume, C Germain, J Goc, MC Dieu-Nosjean, P Validire, L Fournel, L Zitvogel, G Bindea, A Lupo, D Damotte, M Alifano, I Cremer
Journal for ImmunoTherapy of Cancer 2020
Transforming Growth Factor-β: A Multifunctional Regulator of Cancer Immunity
VW Xue, JY Chung, CA Córdoba, AH Cheung, W Kang, EW Lam, KT Leung, KF To, HY Lan, PM Tang
Cancers 2020
Toward a Better Understanding of Bioassays for the Development of Biopharmaceuticals by Exploring the Structure-Antibody-Dependent Cellular Cytotoxicity Relationship in Human Primary Cells
S Wieckowski, C Avenal, AV Orjalo, D Gygax, F Cymer
Frontiers in immunology 2020
Cancer Immunotherapy by Blocking Immune Checkpoints on Innate Lymphocytes
S Pesce, S Trabanelli, CD Vito, M Greppi, V Obino, F Guolo, P Minetto, M Bozzo, M Calvi, E Zaghi, S Candiani, RM Lemoli, C Jandus, D Mavilio, E Marcenaro
Cancers 2020
Diversity of KIRs in invasive breast cancer patients and healthy controls along with the clinical significance in ER/PR/HER2+ patients
MH Larki, S Barani, AR Talei, A Ghaderi
Genes and Immunity 2020
Tumor-Infiltrating Natural Killer Cells
B Cózar, M Greppi, S Carpentier, E Narni-Mancinelli, L Chiossone, E Vivier
Cancer Discovery 2020
Changes in peripheral immune cells after intraoperative radiation therapy in low-risk breast cancer
I Linares-Galiana, MA Berenguer-Frances, R Cañas-Cortés, M Pujol-Canadell, S Comas-Antón, E Martínez, M Laplana, H Pérez-Montero, MJ Pla-Farnós, A Navarro-Martin, M Nuñez, B Both, F Guedea
Journal of Radiation Research 2020
Immune phenotype of patients with stage IV metastatic inflammatory breast cancer
SV Fernandez, AW MacFarlane, M Jillab, MF Arisi, J Yearley, L Annamalai, Y Gong, KQ Cai, RK Alpaugh, M Cristofanilli, KS Campbell
Breast Cancer Research 2020
The Role of Innate Immunity in the Pathogenesis of Breast Cancer
D Grebić, T Gulić, A Starčević, M Alvirović, GB Zagorac, PV Zujić, DV Vujaklija
Breast Care 2020
Oral cancer cell‑derived exosomes modulate natural killer cell activity by regulating the receptors on these cells
X Zhu, X Qin, X Wang, Y Wang, W Cao, J Zhang, W Chen, X Zhu, X Qin, X Wang, Y Wang, W Cao, J Zhang, W Chen, X Zhu, X Qin, X Wang, Y Wang, W Cao, J Zhang, W Chen
International journal of molecular medicine 2020
Natural Killer Cells Expanded and Preactivated Exhibit Enhanced Antitumor Activity against Different Tumor Cells in Vitro
BK Biswas, SA Guru, MP Sumi, E Jamatia, RK Gupta, P Lali, BC Konar, A Saxena, R Mir
Asian Pacific Journal of Cancer Prevention 2020
Regulation of murine NK cell exhaustion through the activation of the DNA damage repair pathway
Maite Alvarez, Federico Simonetta, Jeanette Baker, Antonio Pierrini, Arielle S Wenokur, Alyssa R Morrison, William Murphy, Robert Negrin
JCI Insight 2019
Targetable mechanisms driving immunoevasion of persistent senescent cells link chemotherapy-resistant cancer to aging
Denise Muñoz, Steve Yannone, Anneleen Daemen, Yu Sun, Funda Vakar-Lopez, Misako Kawahara, Adam Freund, Francis Rodier, Jennifer Wu, Pierre-Yves Desprez, David Raulet, Peter S Nelson, Laura J van 't Veer, Judith Campisi, Jean-Philippe Coppé
JCI Insight 2019
blocking expression of inhibitory receptor nkg2a overcomes tumor resistance to nk cells
TAKAHIRO KAMIYA, SEE VOON SEOW, Desmond Wong, MURRAY ROBINSON, Dario Campana
Journal of Clinical Investigation 2019
Killers 2.0: NK Cell Therapies at the Forefront of Cancer Control
Jonathan J. Hodgins, Sarwat Khan, Maria M. Park, Rebecca Auer, Michele Ardolino
Journal of Clinical Investigation 2019
Targeting the TIGIT-PVR immune checkpoint axis as novel therapeutic option in breast cancer
H Stamm, L Oliveira-Ferrer, EM Grossjohann, J Muschhammer, V Thaden, F Brauneck, R Kischel, V Müller, C Bokemeyer, W Fiedler, J Wellbrock
OncoImmunology 2019
Monalizumab: inhibiting the novel immune checkpoint NKG2A
T van Hall, P André, A Horowitz, DF Ruan, L Borst, R Zerbib, E Narni-Mancinelli, SH van der Burg, E Vivier
Journal for ImmunoTherapy of Cancer 2019
Harnessing NK Cells for Cancer Treatment
P Minetto, F Guolo, S Pesce, M Greppi, V Obino, E Ferretti, S Sivori, C Genova, RM Lemoli, E Marcenaro
Frontiers in immunology 2019
Overcoming Resistance to Natural Killer Cell Based Immunotherapies for Solid Tumors
G Nayyar, Y Chu, MS Cairo
Frontiers in Oncology 2019
Dysregulation of Natural Killer Cells in Obesity
D OShea, AE Hogan
Cancers 2019
NKG2D/NKG2-Ligand Pathway Offers New Opportunities in Cancer Treatment
A Frazao, L Rethacker, M Messaoudene, MF Avril, A Toubert, N Dulphy, A Caignard
Frontiers in immunology 2019
Lymphopenia in Cancer Patients and its Effects on Response to Immunotherapy: an opportunity for combination with Cytokines?
C Ménétrier-Caux, I Ray-Coquard, JY Blay, C Caux
Journal for ImmunoTherapy of Cancer 2019
A Natural Impact: NK Cells at the Intersection of Cancer and HIV Disease
O Lucar, RK Reeves, S Jost
Frontiers in immunology 2019
NK Cell Dysfunction and Checkpoint Immunotherapy
J Bi, Z Tian
Frontiers in immunology 2019
Development and validation of nomograms integrating immune-related genomic signatures with clinicopathologic features to improve prognosis and predictive value of triple-negative breast cancer: A gene expression-based retrospective study
K Wang, HL Li, YF Xiong, Y Shi, ZY Li, J Li, X Zhang, HY Li
Cancer Medicine 2019
Phenotype and Function of Activated Natural Killer Cells From Patients With Prostate Cancer: Patient-Dependent Responses to Priming and IL-2 Activation
SP Hood, GA Foulds, H Imrie, S Reeder, SE McArdle, M Khan, AG Pockley
Frontiers in immunology 2019
NKG2A Down-Regulation by Dasatinib Enhances Natural Killer Cytotoxicity and Accelerates Effective Treatment Responses in Patients With Chronic Myeloid Leukemia
MC Chang, HI Cheng, K Hsu, YN Hsu, CW Kao, YF Chang, KH Lim, CG Chen
Frontiers in immunology 2019
Focused Ultrasound Improves NK-92MI Cells Infiltration Into Tumors
C Yang, M Du, F Yan, Z Chen
Frontiers in pharmacology 2019
Endometrial Tumor Microenvironment Alters Human NK Cell Recruitment, and Resident NK Cell Phenotype and Function
C Degos, M Heinemann, J Barrou, N Boucherit, E Lambaudie, A Savina, L Gorvel, D Olive
Frontiers in immunology 2019
A novel combination of chemotherapy and immunotherapy controls tumor growth in mice with a human immune system
A Burlion, RN Ramos, P KC, K Sendeyo, A Corneau, C Ménétrier-Caux, E Piaggio, D Olive, C Caux, G Marodon
OncoImmunology 2019
Natural Killer Cells as Key Players of Tumor Progression and Angiogenesis: Old and Novel Tools to Divert Their Pro-Tumor Activities into Potent Anti-Tumor Effects
B Bassani, D Baci, M Gallazzi, A Poggi, A Bruno, L Mortara
Cancers 2019
TNF-α-induced Tim-3 expression marks the dysfunction of infiltrating natural killer cells in human esophageal cancer
Y Zheng, Y Li, J Lian, H Yang, F Li, S Zhao, Y Qi, Y Zhang, L Huang
Journal of Translational Medicine 2019
Tumor-Derived Extracellular Vesicles Inhibit Natural Killer Cell Function in Pancreatic Cancer
J Zhao, HA Schlößer, Z Wang, J Qin, J Li, F Popp, MC Popp, H Alakus, SH Chon, HP Hansen, WF Neiss, KW Jauch, CJ Bruns, Y Zhao
Cancers 2019
CD56 expression in breast cancer induces sensitivity to natural killer-mediated cytotoxicity by enhancing the formation of cytotoxic immunological synapse
G Taouk, O Hussein, M Zekak, A Abouelghar, Y Al-Sarraj, EM Abdelalim, M Karam
Scientific Reports 2019
Human peripheral blood DNAM-1 neg NK cells are a terminally differentiated subset with limited effector functions
KA Stannard, S Lemoine, NJ Waterhouse, F Vari, L Chatenoud, MK Gandhi, L Martinet, MJ Smyth, C Guillerey
Blood Advances 2019
The Obesity Paradox in Cancer, Tumor Immunology, and Immunotherapy: Potential Therapeutic Implications in Triple Negative Breast Cancer
A Naik, AM Monjazeb, J Decock
Frontiers in immunology 2019
Natural Killer Cell Recruitment and Activation Are Regulated by CD47 Expression in the Tumor Microenvironment
PR Nath, D Pal-Nath, A Mandal, MC Cam, AL Schwartz, DD Roberts
Cancer immunology research 2019
Different Features of Tumor-Associated NK Cells in Patients With Low-Grade or High-Grade Peritoneal Carcinomatosis
S Pesce, V Belgrano, M Greppi, S Carlomagno, M Squillario, A Barla, MD Chiesa, SD Domenico, D Mavilio, L Moretta, S Candiani, S Sivori, FD Cian, E Marcenaro
Frontiers in immunology 2019
NK Cell Plasticity in Cancer
S Liu, P Dhar, JD Wu
Journal of Clinical Medicine 2019
The Immune Microenvironment of Breast Cancer Progression
Tower, Ruppert, Britt
Cancers 2019
Impact of Tumor and Immunological Heterogeneity on the Anti-Cancer Immune Response
Shembrey, Huntington, Hollande
Cancers 2019
The Rise of NK Cell Checkpoints as Promising Therapeutic Targets in Cancer Immunotherapy
H Sun, C Sun
Frontiers in immunology 2019
IL-15 superagonist RLI has potent immunostimulatory properties on NK cells: implications for antimetastatic treatment
M Desbois, C Béal, M Charrier, B Besse, G Meurice, N Cagnard, Y Jacques, D Béchard, L Cassard, N Chaput
Journal for ImmunoTherapy of Cancer 2019
Immunometabolism: A new target for improving cancer immunotherapy
Guo C, Chen S, Liu W, Ma Y, Li J, Fisher PB, Fang X, Wang XY
Advances in cancer research 2019
A potential role for peripheral natural killer cell activity induced by preoperative chemotherapy in breast cancer patients.
Kim R, Kawai A, Wakisaka M, Funaoka Y, Yasuda N, Hidaka M, Morita Y, Ohtani S, Ito M, Arihiro K
Cancer Immunology, Immunotherapy 2019
Eya3 promotes breast tumor-associated immune suppression via threonine phosphatase-mediated PD-L1 upregulation
Rebecca Vartuli, Hengbo Zhou, Lingdi Zhang, Rani Powers, Jared Klarquist, Pratyaydipta Rudra, Melanie Vincent, Debashis Ghosh, James Costello, Ross M Kedl, Jill Slansky, Rui Zhao, Heide Ford
Journal of Clinical Investigation 2018
Nitric Oxide Production by Myeloid-Derived Suppressor Cells Plays a Role in Impairing Fc Receptor–Mediated Natural Killer Cell Function
A Stiff, P Trikha, B Mundy-Bosse, E McMichael, TA Mace, B Benner, K Kendra, A Campbell, S Gautam, D Abood, I Landi, V Hsu, M Duggan, R Wesolowski, M Old, JH Howard, L Yu, N Stasik, T Olencki, N Muthusamy, S Tridandapani, JC Byrd, M Caligiuri, WE Carson
Clinical cancer research 2018
Interaction of PVR/PVRL2 with TIGIT/DNAM-1 as a novel immune checkpoint axis and therapeutic target in cancer
H Stamm, J Wellbrock, W Fiedler
Mammalian Genome 2018
Targeting PVR (CD155) and its receptors in anti-tumor therapy
PK Brlić, TL Roviš, G Cinamon, P Tsukerman, O Mandelboim, S Jonjić
Cellular and Molecular Immunology 2018
Prognostic values of the mRNA expression of natural killer receptor ligands and their association with clinicopathological features in breast cancer patients
A Abouelghar, R Hasnah, G Taouk, M Saad, M Karam
Oncotarget 2018
Mechanisms of immune evasion in breast cancer
JP Bates, R Derakhshandeh, L Jones, TJ Webb
BMC Cancer 2018
Does the Immunocompetent Status of Cancer Patients Have an Impact on Therapeutic DC Vaccination Strategies?
SM Lluesma, M Graciotti, C Chiang, L Kandalaft
Human vaccines 2018
Natural killer cells in liver diseases
M Zheng, H Sun, Z Tian
Frontiers of Medicine 2018
Immune-Phenotyping and Transcriptomic Profiling of Peripheral Blood Mononuclear Cells From Patients With Breast Cancer: Identification of a 3 Gene Signature Which Predicts Relapse of Triple Negative Breast Cancer
GA Foulds, J Vadakekolathu, TM Abdel-Fatah, D Nagarajan, S Reeder, C Johnson, S Hood, PM Moseley, SY Chan, AG Pockley, S Rutella, SE McArdle
Frontiers in immunology 2018
A Novel Feeder-free System for Mass Production of Murine Natural Killer Cells In Vitro
PM Tang, PC Tang, JY Chung, JS Hung, QM Wang, GY Lian, J Sheng, XR Huang, KF To, HY Lan
Journal of visualized experiments : JoVE 2018
Cancer risk in patients with alopecia areata: a nationwide population-based matched cohort study
CC Chen, YT Chang, HN Liu, YJ Chen
Cancer Medicine 2018
IL-15 Overcomes Hepatocellular Carcinoma-Induced NK Cell Dysfunction
NJ Easom, KA Stegmann, L Swadling, LJ Pallett, AR Burton, D Odera, N Schmidt, WC Huang, G Fusai, B Davidson, MK Maini
Frontiers in immunology 2018
Amino acid-dependent cMyc expression is essential for NK cell metabolic and functional responses in mice
RM Loftus, N Assmann, N Kedia-Mehta, KL OBrien, A Garcia, C Gillespie, JL Hukelmann, PJ Oefner, AI Lamond, CM Gardiner, K Dettmer, DA Cantrell, LV Sinclair, DK Finlay
Nature Communications 2018
Natural Killer Cells from Malignant Pleural Effusion Are Endowed with a Decidual-Like Proangiogenic Polarization
A Bosi, S Zanellato, B Bassani, A Albini, A Musco, M Cattoni, M Desio, E Nardecchia, DG DUrso, A Imperatori, L Dominioni, DM Noonan, L Mortara, A Bruno
Journal of Immunology Research 2018
High mammographic density in women is associated with protumor inflammation
CW Huo, P Hill, G Chew, PJ Neeson, H Halse, ED Williams, MA Henderson, EW Thompson, KL Britt
Breast Cancer Research 2018
NKG2A Expression Is Not per se Detrimental for the Anti-Multiple Myeloma Activity of Activated Natural Killer Cells in an In Vitro System Mimicking the Tumor Microenvironment
NM Mahaweni, FA Ehlers, S Sarkar, JW Janssen, MG Tilanus, GM Bos, L Wieten
Frontiers in immunology 2018
Altered NKp30, NKp46, NKG2D, and DNAM-1 Expression on Circulating NK Cells Is Associated with Tumor Progression in Human Gastric Cancer
B Han, F Mao, Y Zhao, Y Lv, Y Teng, M Duan, W Chen, P Cheng, T Wang, Z Liang, J Zhang, Y Liu, G Guo, Q Zou, Y Zhuang, L Peng
Journal of Immunology Research 2018
Epigenetic priming of both tumor and NK cells augments antibody-dependent cellular cytotoxicity elicited by the anti-PD-L1 antibody avelumab against multiple carcinoma cell types
KC Hicks, M Fantini, RN Donahue, A Schwab, KM Knudson, SR Tritsch, C Jochems, PE Clavijo, CT Allen, JW Hodge, KY Tsang, J Schlom, SR Gameiro
OncoImmunology 2018
Suppression of autophagy and HCK signaling promotes PTGS2 high FCGR3 − NK cell differentiation triggered by ectopic endometrial stromal cells
J Mei, WJ Zhou, XY Zhu, H Lu, K Wu, HL Yang, Q Fu, CY Wei, KK Chang, LP Jin, J Wang, YM Wang, DJ Li, MQ Li
Autophagy 2018
Oncogenes in immune cells as potential therapeutic targets
GK Zakiryanova, S Wheeler, MR Shurin
ImmunoTargets and Therapy 2018
Combined peripheral natural killer cell and circulating tumor cell enumeration enhance prognostic efficiency in patients with metastatic triple-negative breast cancer
X Liu, R Ran, B Shao, HS Rugo, Y Yang, Z Hu, Z Wei, F Wan, W Kong, G Song, H Jiang, X Liang, R Zhang, Y Yan, G Xu, H Li
Chinese Journal of Cancer Research 2018
A phase 1 study of lirilumab (antibody against killer immunoglobulin-like receptor antibody KIR2D; IPH2102) in patients with solid tumors and hematologic malignancies
N Vey, L Karlin, S Sadot-Lebouvier, F Broussais, D Berton-Rigaud, J Rey, A Charbonnier, D Marie, P André, C Paturel, R Zerbib, J Bennouna, G Salles, A Gonçalves
Oncotarget 2018
Shining light on the significance of NK cell CD56 brightness
SM Poznanski, AA Ashkar
Cellular and Molecular Immunology 2018
Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells
P André, C Denis, C Soulas, C Bourbon-Caillet, J Lopez, T Arnoux, M Bléry, C Bonnafous, L Gauthier, A Morel, B Rossi, R Remark, V Breso, E Bonnet, G Habif, S Guia, AI Lalanne, C Hoffmann, O Lantz, J Fayette, A Boyer-Chammard, R Zerbib, P Dodion, H Ghadially, M Jure-Kunkel, Y Morel, R Herbst, E Narni-Mancinelli, RB Cohen, E Vivier
Cell 2018
Circulating NKp46 + Natural Killer cells have a potential regulatory property and predict distinct survival in Non-Small Cell Lung Cancer
E Picard, Y Godet, C Laheurte, M Dosset, J Galaine, L Beziaud, R Loyon, L Boullerot, EL Joseph, M Jacquin, G Eberst, FL pimpec-Barthes, E Fabre, V Westeel, A Caignard, C Borg, O Adotévi
OncoImmunology 2018
Engineering Natural Killer Cells for Cancer Immunotherapy
K Rezvani, R Rouce, E Liu, E Shpall
Molecular Therapy 2017
Patient’s Natural Killer Cells in the Era of Targeted Therapies: Role for Tumor Killers
M Messaoudene, A Frazao, PJ Gavlovsky, A Toubert, N Dulphy, A Caignard
Frontiers in immunology 2017
Interplay between Natural Killer Cells and Anti-HER2 Antibodies: Perspectives for Breast Cancer Immunotherapy
A Muntasell, M Cabo, S Servitja, I Tusquets, M Martínez-García, A Rovira, F Rojo, J Albanell, M López-Botet
Frontiers in immunology 2017
STATs in NK-Cells: The Good, the Bad, and the Ugly
D Gotthardt, V Sexl
Frontiers in immunology 2017
Adipocytes and Macrophages Interplay in the Orchestration of Tumor Microenvironment: New Implications in Cancer Progression
LH Corrêa, R Corrêa, CM Farinasso, LP de Dourado, KG Magalhães
Frontiers in immunology 2017
Regulation of mTOR, Metabolic Fitness, and Effector Functions by Cytokines in Natural Killer Cells
S Viel, L Besson, M Marotel, T Walzer, A Marçais
Cancers 2017
Restoring Natural Killer Cell Immunity against Multiple Myeloma in the Era of New Drugs
G Pittari, L Vago, M Festuccia, C Bonini, D Mudawi, L Giaccone, B Bruno
Frontiers in immunology 2017
Association between inflammation and cancer stem cell phenotype in breast cancer
Y Jeong, H Oh, S Park, J Bong
Oncology Letters 2017
Loss of natural killer T cells promotes pancreatic cancer in LSL-Kras G12D/+ mice
NB Janakiram, A Mohammed, T Bryant, R Ritchie, N Stratton, L Jackson, S Lightfoot, DM Benbrook, AS Asch, ML Lang, CV Rao
Immunology 2017
MicroRNA-519a-3p mediates apoptosis resistance in breast cancer cells and their escape from recognition by natural killer cells
C Breunig, J Pahl, M Küblbeck, M Miller, D Antonelli, N Erdem, C Wirth, R Will, A Bott, A Cerwenka, S Wiemann
Cell Death and Disease 2017
IL15 induces a potent anti-tumor activity in NK cells isolated from malignant pleural effusions and overcomes the inhibitory effect of pleural fluid
C Daniele, S Martini, L Chiossone, F Scordamaglia, CF Simonassi, L Moretta, MC Mingari, P Vacca
OncoImmunology 2017
Kinetics of Cytotoxic Lymphocytes Reconstitution after Induction Chemotherapy in Elderly AML Patients Reveals Progressive Recovery of Normal Phenotypic and Functional Features in NK Cells
J Rey, C Fauriat, E Kochbati, F Orlanducci, A Charbonnier, E DIncan, P Andre, F Romagne, B Barbarat, N Vey, D Olive
Frontiers in immunology 2017
Altered expression of miR-181a and miR-146a does not change the expression of surface NCRs in human NK cells
M Rady, C Watzl, M Claus, O Khorshid, L Mahran, K Abou-Aisha
Scientific Reports 2017
Smad3 promotes cancer progression by inhibiting E4BP4-mediated NK cell development
PM Tang, S Zhou, XM Meng, QM Wang, CJ Li, GY Lian, XR Huang, YJ Tang, XY Guan, BP Yan, KF To, HY Lan
Nature Communications 2017
Natural Killers Are Made Not Born: How to Exploit NK Cells in Lung Malignancies
P Carrega, G Ferlazzo
Frontiers in immunology 2017
Role of Distinct Natural Killer Cell Subsets in Anticancer Response
H Stabile, C Fionda, A Gismondi, A Santoni
Frontiers in immunology 2017
What Fuels Natural Killers? Metabolism and NK Cell Responses
CM Gardiner, DK Finlay
Frontiers in immunology 2017
NKG2D+CD4+ T Cells Kill Regulatory T Cells in a NKG2D-NKG2D Ligand- Dependent Manner in Systemic Lupus Erythematosus
D Yang, Z Tian, M Zhang, W Yang, J Tang, Y Wu, B Ni
Scientific Reports 2017
Leveraging natural killer cells for cancer immunotherapy
SK Grossenbacher, EG Aguilar, WJ Murphy
Immunotherapy 2017
The Rise of Allogeneic Natural Killer Cells As a Platform for Cancer Immunotherapy: Recent Innovations and Future Developments
JP Veluchamy, N Kok, HJ van der Vliet, HM Verheul, TD de Gruijl, J Spanholtz
Frontiers in immunology 2017
On-treatment decrease of NKG2D correlates to early emergence of clinically evident hepatocellular carcinoma after interferon-free therapy for chronic hepatitis C
P Chu, N Nakamoto, N Taniki, K Ojiro, T Amiya, Y Makita, H Murata, A Yamaguchi, S Shiba, R Miyake, T Katayama, A Ugamura, A Ikura, K Takeda, H Ebinuma, H Saito, T Kanai, CH Liu
PloS one 2017
New insights into the role of EMT in tumor immune escape
S Terry, P Savagner, S Ortiz-Cuaran, L Mahjoubi, P Saintigny, JP Thiery, S Chouaib
Molecular Oncology 2017
NK Cell Exhaustion
J Bi, Z Tian
Frontiers in immunology 2017
CD155, an onco-immunologic molecule in human tumors
J Gao, Q Zheng, N Xin, W Wang, C Zhao
Cancer Science 2017
Ex vivo expanded natural killer cells from breast cancer patients and healthy donors are highly cytotoxic against breast cancer cell lines and patient-derived tumours
MM Shenouda, A Gillgrass, T Nham, R Hogg, AJ Lee, MV Chew, M Shafaei, C Aarts, DA Lee, J Hassell, A Bane, S Dhesy-Thind, AA Ashkar
Breast Cancer Research 2017
IL-15, TIM-3 and NK cells subsets predict responsiveness to anti-CTLA-4 treatment in melanoma patients
R Tallerico, CM Cristiani, E Staaf, C Garofalo, R Sottile, M Capone, YP de Coaña, G Madonna, E Palella, M Wolodarski, V Carannante, D Mallardo, E Simeone, AM Grimaldi, S Johansson, P Frumento, E Gulletta, A Anichini, F Colucci, G Ciliberto, R Kiessling, K Kärre, PA Ascierto, E Carbone
OncoImmunology 2016
NKp30 isoforms and NKp30 ligands are predictive biomarkers of response to imatinib mesylate in metastatic GIST patients
S Rusakiewicz, A Perier, M Semeraro, JM Pitt, EP von Strandmann, KS Reiners, S Aspeslagh, C Pipéroglou, F Vély, A Ivagnes, S Jegou, N Halama, L Chaigneau, P Validire, C Christidis, T Perniceni, B Landi, A Berger, N Isambert, J Domont, S Bonvalot, P Terrier, J Adam, JM Coindre, JF Emile, V Poirier-Colame, K Chaba, B Rocha, A Caignard, A Toubert, D Enot, J Koch, A Marabelle, M Lambert, S Caillat-Zucman, S Leyvraz, C Auclair, E Vivier, A Eggermont, C Borg, JY Blay, AL Cesne, O Mir, L Zitvogel
OncoImmunology 2016
Progressive changes in composition of lymphocytes in lung tissues from patients with non-small-cell lung cancer
MM Valenzuela-Membrives, F Perea-García, A Sanchez-Palencia, F Ruiz-Cabello, M Gómez-Morales, MT Miranda-León, I Galindo-Angel, ME Fárez-Vidal
Oncotarget 2016
VEGFR2 targeted antibody fused with MICA stimulates NKG2D mediated immunosurveillance and exhibits potent anti-tumor activity against breast cancer
W Xei, F Liu, Y Wang, X Ren, T Wang, Z Chen, M Tang, F Sun, Z Li, M Wang, J Zhang
Oncotarget 2016
NKp30 isoforms and NKp46 transcripts in metastatic melanoma patients: unique NKp30 pattern in rare melanoma patients with favorable evolution
M Messaoudene, G Fregni, D Enot, N Jacquelot, E Neves, N Germaud, HJ Garchon, W Boukouaci, R Tamouza, J Chanal, MF Avril, A Toubert, L Zitvogel, S Rusakiewicz, A Caignard
OncoImmunology 2016
NK Cells, Tumor Cell Transition, and Tumor Progression in Solid Malignancies: New Hints for NK-Based Immunotherapy?
C Cantoni, L Huergo-Zapico, M Parodi, M Pedrazzi, MC Mingari, A Moretta, B Sparatore, S Gonzalez, D Olive, C Bottino, R Castriconi, M Vitale
Journal of Immunology Research 2016
Human NK Cell Subsets in Pregnancy and Disease: Toward a New Biological Complexity
CM Cristiani, E Palella, R Sottile, R Tallerico, C Garofalo, E Carbone
Frontiers in immunology 2016
Decreased NK-cell tumour immunosurveillance consequent to JAK inhibition enhances metastasis in breast cancer models
A Bottos, D Gotthardt, JW Gill, A Gattelli, A Frei, A Tzankov, V Sexl, A Wodnar-Filipowicz, NE Hynes
Nature Communications 2016
Coordinated Activation of Toll-Like Receptor8 (TLR8) and NLRP3 by the TLR8 Agonist, VTX-2337, Ignites Tumoricidal Natural Killer Cell Activity
GN Dietsch, H Lu, Y Yang, C Morishima, LQ Chow, ML Disis, RM Hershberg, H Nishikawa
PloS one 2016
Modulation of innate immunity in the tumor microenvironment
E Gonzalez-Gugel, M Saxena, N Bhardwaj
Cancer Immunology, Immunotherapy 2016
Progress towards understanding heterotypic interactions in multi-culture models of breast cancer
MC Regier, ET Alarid, DJ Beebe
Integrative Biology 2016
Natural killer cells phenotypic characterization as an outcome predictor of HCV-linked HCC after curative treatments
E Cariani, M Pilli, V Barili, E Porro, E Biasini, A Olivani, RD Valle, T Trenti, C Ferrari, G Missale
OncoImmunology 2016
Progressive natural killer cell dysfunction associated with alterations in subset proportions and receptor expression in soft-tissue sarcoma patients
V Bücklein, T Adunka, AN Mendler, R Issels, M Subklewe, JC Schmollinger, E Noessner
OncoImmunology 2016
Altered Expression of Natural Cytotoxicity Receptors and NKG2D on Peripheral Blood NK Cell Subsets in Breast Cancer Patients
NG Nieto-Velázquez, YD Torres-Ramos, JL Muñoz-Sánchez, L Espinosa-Godoy, S Gómez-Cortés, J Moreno, MA Moreno-Eutimio
Translational oncology 2016
Liver-infiltrating CD11b−CD27− NK subsets account for NK-cell dysfunction in patients with hepatocellular carcinoma and are associated with tumor progression
QF Zhang, WW Yin, Y Xia, YY Yi, QF He, X Wang, H Ren, DZ Zhang
Cellular and Molecular Immunology 2016
A prognostic risk model for patients with triple negative breast cancer based on stromal natural killer cells, tumor-associated macrophages and growth-arrest specific protein 6
W Tian, L Wang, L Yuan, W Duan, W Zhao, S Wang, Q Zhang
Cancer Science 2016
Ionomycin Treatment Renders NK Cells Hyporesponsive
G Romera-Cárdenas, LM Thomas, S Lopez-Cobo, EM García-Cuesta, EO Long, HT Reyburn, J Yu
PloS one 2016
High NKG2A expression contributes to NK cell exhaustion and predicts a poor prognosis of patients with liver cancer
C Sun, J Xu, Q Huang, M Huang, H Wen, C Zhang, J Wang, J Song, M Zheng, H Sun, H Wei, W Xiao, R Sun, Z Tian
OncoImmunology 2016
Phenotypic and Functional Dysregulated Blood NK Cells in Colorectal Cancer Patients Can Be Activated by Cetuximab Plus IL-2 or IL-15
YS Rocca, MP Roberti, EP Juliá, MB Pampena, L Bruno, S Rivero, E Huertas, FS Loria, A Pairola, A Caignard, J Mordoh, EM Levy
Frontiers in immunology 2016
NKp44 and NKp30 splice variant profiles in decidua and tumor tissues: a comparative viewpoint
A Shemesh, A Kugel, N Steiner, M Yezersky, D Tirosh, A Edri, O Teltsh, B Rosental, E Sheiner, E Rubin, KS Campbell, A Porgador
Oncotarget 2016
From mice to humans: developments in cancer immunoediting
Michele Teng, Jerome GALON, Wolf-Herman Fridman, Mark Smyth
Journal of Clinical Investigation 2015
The TGF-β/SMAD pathway is an important mechanism for NK cell immune evasion in childhood B-acute lymphoblastic leukemia
RH Rouce, H Shaim, T Sekine, G Weber, B Ballard, S Ku, C Barese, V Murali, MF Wu, H Liu, EJ Shpall, CM Bollard, KR Rabin, K Rezvani
Leukemia 2015
Immune cell dysfunctions in breast cancer patients detected through whole blood multi-parametric flow cytometry assay
E Verronèse, A Delgado, J Valladeau-Guilemond, G Garin, S Guillemaut, O Tredan, I Ray-Coquard, T Bachelot, A N'Kodia, C Bardin-Dit-Courageot, C Rigal, D Pérol, C Caux, C Ménétrier-Caux
OncoImmunology 2015
Tertiary Lymphoid Structure-Associated B Cells are Key Players in Anti-Tumor Immunity
C Germain, S Gnjatic, MC Dieu-Nosjean
Frontiers in immunology 2015
Natural Killer Cell Immunomodulation: Targeting Activating, Inhibitory, and Co-stimulatory Receptor Signaling for Cancer Immunotherapy
C Chester, K Fritsch, HE Kohrt
Frontiers in immunology 2015
Natural Killer Cells as Helper Cells in Dendritic Cell Cancer Vaccines
MÃ Pampena, EM Levy
Frontiers in immunology 2015
Balancing natural killer cell activation through paired receptors
L Martinet, MJ Smyth
Nature Reviews Immunology 2015
Newtonian cell interactions shape natural killer cell education
JP Goodridge, B Önfelt, KJ Malmberg
Immunological Reviews 2015
Inherent transcriptional signatures of NK cells are associated with response to IFNα + rivabirin therapy in patients with Hepatitis C Virus
ML Ascierto, F Bozzano, D Bedognetti, F Marras, C Schechterly, K Matsuura, A Picciotto, S Marenco, Y Zhao, V DeGiorgi, M Sommariva, L Moretta, E Wang, HJ Alter, FM Marincola, AD Maria
Journal of Translational Medicine 2015
Blockade of MMP14 Activity in Murine Breast Carcinomas: Implications for Macrophages, Vessels, and Radiotherapy
EI Ager, SV Kozin, ND Kirkpatrick, G Seano, DP Kodack, V Askoxylakis, Y Huang, S Goel, M Snuderl, A Muzikansky, DM Finkelstein, DT Dransfield, L Devy, Y Boucher, D Fukumura, RK Jain
JNCI Journal of the National Cancer Institute 2015
Adipose cells promote resistance of breast cancer cells to trastuzumab-mediated antibody-dependent cellular cytotoxicity
MN Duong, A Cleret, EL Matera, K Chettab, D Mathé, S Valsesia-Wittmann, B Clémenceau, C Dumontet
Breast Cancer Research 2015
Overexpression of IL-15 promotes tumor destruction via NK1.1+ cells in a spontaneous breast cancer model
AE Gillgrass, MV Chew, T Krneta, AA Ashkar
BMC Cancer 2015
Therapeutic Potential and Challenges of Natural Killer Cells in Treatment of Solid Tumors
AG Navarro, AT Björklund, M Chekenya
Frontiers in immunology 2015
Cytotoxicity and infiltration of human NK cells in in vivo-like tumor spheroids
A Giannattasio, S Weil, S Kloess, N Ansari, EH Stelzer, A Cerwenka, A Steinle, U Koehl, J Koch
BMC Cancer 2015
Adenanthin, a new inhibitor of thiol-dependent antioxidant enzymes, impairs the effector functions of human natural killer cells
M Siernicka, M Winiarska, M Bajor, M Firczuk, A Muchowicz, M Bobrowicz, C Fauriat, J Golab, D Olive, R Zagozdzon
Immunology 2015
NK Cell Inflammation in the Clinical Outcome of Colorectal Carcinoma
A Coppola, R Arriga, D Lauro, MI Principe, F Buccisano, L Maurillo, P Palomba, A Venditti, G Sconocchia
Frontiers in Medicine 2015
Natural Killer (NK)/melanoma cell interaction induces NK-mediated release of chemotactic High Mobility Group Box-1 (HMGB1) capable of amplifying NK cell recruitment
M Parodi, M Pedrazzi, C Cantoni, M Averna, M Patrone, M Cavaletto, S Spertino, D Pende, M Balsamo, G Pietra, S Sivori, S Carlomagno, MC Mingari, L Moretta, B Sparatore, M Vitale
OncoImmunology 2015
CTLA-4+ Regulatory T Cells Increased in Cetuximab-Treated Head and Neck Cancer Patients Suppress NK Cell Cytotoxicity and Correlate with Poor Prognosis
HB Jie, PJ Schuler, SC Lee, RM Srivastava, A Argiris, S Ferrone, TL Whiteside, RL Ferris
Cancer research 2015
The breast tumor microenvironment alters the phenotype and function of natural killer cells
T Krneta, A Gillgrass, M Chew, AA Ashkar
Cellular and Molecular Immunology 2015
Human natural killer cells: news in the therapy of solid tumors and high-risk leukemias
G Pietra, C Vitale, D Pende, A Bertaina, F Moretta, M Falco, P Vacca, E Montaldo, C Cantoni, MC Mingari, A Moretta, F Locatelli, L Moretta
Cancer Immunology, Immunotherapy 2015
Potential Use of Natural Killer Cell Transfer Therapy in the Perioperative Period to Improve Oncologic Outcomes
JP Cata, C Conrad, K Rezvani
Scientifica 2015
Increased NK Cell Maturation in Patients with Acute Myeloid Leukemia
AS Chretien, S Granjeaud, F Gondois-Rey, S Harbi, F Orlanducci, D Blaise, N Vey, C Arnoulet, C Fauriat, D Olive
Frontiers in immunology 2015
Inhibitory leukocyte immunoglobulin-like receptors: Immune checkpoint proteins and tumor sustaining factors
X Kang, J Kim, M Deng, S John, H Chen, G Wu, H Phan, CC Zhang
Cell cycle (Georgetown, Tex.) 2015
The Application of Natural Killer Cell Immunotherapy for the Treatment of Cancer
K Rezvani, RH Rouce
Frontiers in immunology 2015
NK cell exhaustion: bad news for chronic disease?
JL Schafer, MC Müller-Trutwin, RK Reeves
Oncotarget 2015
Highly effective NK cells are associated with good prognosis in patients with metastatic prostate cancer
Pasero C, Gravis G, Granjeaud S, Guerin M, Thomassin-Piana J, Rocchi P, Salem N, Walz J, Moretta A, Olive D
Oncotarget 2015
Cytokines reinstate NK cell-mediated cancer immunosurveillance
Laurence Zitvogel, Guido Kroemer
Journal of Clinical Investigation 2014
Reversal of NK-cell exhaustion in advanced melanoma by Tim-3 blockade
IP da Silva, A Gallois, S Jimenez-Baranda, S Khan, AC Anderson, VK Kuchroo, I Osman, N Bhardwaj
Cancer immunology research 2014
Cancer-Induced Alterations of NK-Mediated Target Recognition: Current and Investigational Pharmacological Strategies Aiming at Restoring NK-Mediated Anti-Tumor Activity
AS Chretien, AL Roy, N Vey, T Prebet, D Blaise, C Fauriat, D Olive
Frontiers in immunology 2014
Clinical utility of natural killer cells in cancer therapy and transplantation
DA Knorr, V Bachanova, MR Verneris, JS Miller
Seminars in Immunology 2014
Microenvironment of Tumor-Draining Lymph Nodes: Opportunities for Liposome-Based Targeted Therapy
S Chandrasekaran, M King
International journal of molecular sciences 2014
A Think Tank of TINK/TANKs: Tumor-Infiltrating/Tumor-Associated Natural Killer Cells in Tumor Progression and Angiogenesis
A Bruno, G Ferlazzo, A Albini, DM Noonan
JNCI Journal of the National Cancer Institute 2014
The receptors CD96 and CD226 oppose each other in the regulation of natural killer cell functions
CJ Chan, L Martinet, S Gilfillan, F Souza-Fonseca-Guimaraes, MT Chow, L Town, DS Ritchie, M Colonna, DM Andrews, MJ Smyth
Nature Immunology 2014
Stromal Fibroblasts and the Immune Microenvironment: Partners in Mammary Gland Biology and Pathology?
A Unsworth, R Anderson, K Britt
Journal of Mammary Gland Biology and Neoplasia 2014
Human NK Cells: From Surface Receptors to the Therapy of Leukemias and Solid Tumors
L Moretta, G Pietra, E Montaldo, P Vacca, D Pende, M Falco, GD Zotto, F Locatelli, A Moretta, MC Mingari
Frontiers in immunology 2014
NK cell receptor imbalance and NK cell dysfunction in HBV infection and hepatocellular carcinoma
C Sun, H Sun, C Zhang, Z Tian
Cellular and Molecular Immunology 2014
NK cells and T cells cooperate during the clinical course of colorectal cancer
G Sconocchia, S Eppenberger, GC Spagnoli, L Tornillo, R Droeser, S Caratelli, F Ferrelli, A Coppola, R Arriga, D Lauro, G Iezzi, L Terracciano, S Ferrone
OncoImmunology 2014
Reversal of natural killer cell exhaustion by TIM-3 blockade
A Gallois, I Silva, I Osman, N Bhardwaj
OncoImmunology 2014
mTORC1-Dependent Metabolic Reprogramming Is a Prerequisite for NK Cell Effector Function
RP Donnelly, RM Loftus, SE Keating, KT Liou, CA Biron, CM Gardiner, DK Finlay
Journal of immunology (Baltimore, Md. : 1950) 2014
Victory and Defeat in the Induction of a Therapeutic Response through Vaccine Therapy for Human and Canine Brain Tumors: A Review of the State of the Art
Olin MR, Pluhar GE, Andersen BM, Shaver R, Waldron NN, Moertel CL
Critical reviews in immunology 2014
Rescue of Impaired NK Cell Activity in Hodgkin Lymphoma With Bispecific Antibodies In Vitro and in Patients
KS Reiners, J Kessler, M Sauer, A Rothe, HP Hansen, U Reusch, C Hucke, U Köhl, H Dürkop, A Engert, EP von Strandmann
Molecular Therapy 2013
Peripheral blood mononuclear cells of patients with breast cancer can be reprogrammed to enhance anti-HER-2/neu reactivity and overcome myeloid-derived suppressor cells
KK Payne, CK Zoon, W Wan, K Marlar, RC Keim, MN Kenari, AL Kazim, HD Bear, MH Manjili
Breast Cancer Research and Treatment 2013
Molecular mechanisms of natural killer cell activation in response to cellular stress
CJ Chan, MJ Smyth, L Martinet
Cell Death and Differentiation 2013
Influence of tumors on protective anti-tumor immunity and the effects of irradiation
GA Foulds, J Radons, M Kreuzer, G Multhoff, AG Pockley
Frontiers in Oncology 2013
CD11b(-)CD27(-) NK cells are associated with the progression of lung carcinoma
J Jin, B Fu, X Mei, T Yue, R Sun, Z Tian, H Wei
PloS one 2013
The immune system and inflammation in breast cancer
X Jiang, DJ Shapiro
Molecular and Cellular Endocrinology 2013
A prostaglandin E (PGE) receptor EP4 antagonist protects natural killer cells from PGE2-mediated immunosuppression and inhibits breast cancer metastasis
X Ma, D Holt, N Kundu, J Reader, O Goloubeva, Y Take, AM Fulton
OncoImmunology 2013
Molecular signatures mostly associated with NK cells are predictive of relapse free survival in breast cancer patients
M Ascierto, MO Idowu, Y Zhao, H Khalak, KK Payne, XY Wang, CI Dumur, D Bedognetti, S Tomei, PA Ascierto, A Shanker, HD Bear, E Wang, FM Marincola, AD Maria, MH Manjili
Journal of Translational Medicine 2013
NK cells from malignant pleural effusions are potent antitumor effectors
P Vacca, S Martini, MC Mingari, L Moretta
OncoImmunology 2013
When breast cancer cells start to fend the educational process of NK cells off
E Mamessier, C Bourgin, D Olive
OncoImmunology 2013
Comprehensive analysis of the percentage of surface receptors and cytotoxic granules positive natural killer cells in patients with pancreatic cancer, gastric cancer, and colorectal cancer
YP Peng, Y Zhu, JJ Zhang, ZK Xu, ZY Qian, CC Dai, KR Jiang, JL Wu, WT Gao, Q Li, Q Du, Y Miao
Journal of Translational Medicine 2013
Glycocalyx engineering reveals a Siglec-based mechanism for NK cell immunoevasion
JE Hudak, SM Canham, CR Bertozzi
Nature Chemical Biology 2013
Homo-oligomerization of the Activating Natural Killer Cell Receptor NKp30 Ectodomain Increases Its Binding Affinity for Cellular Ligands
J Herrmann, H Berberich, J Hartmann, S Beyer, K Davies, J Koch
The Journal of biological chemistry 2013
Lung Tumor Microenvironment Induces Specific Gene Expression Signature in Intratumoral NK Cells
M Gillard-Bocquet, C Caer, N Cagnard, L Crozet, M Perez, WH Fridman, C Sautès-Fridman, I Cremer
Frontiers in immunology 2013
NK cells sense tumors, course of disease and treatments
G Fregni, A Perier, MF Avril, A Caignard
OncoImmunology 2012
Primary B-CLL Resistance to NK Cell Cytotoxicity can be Overcome In Vitro and In Vivo by Priming NK Cells and Monoclonal Antibody Therapy
C Veuillen, T Aurran-Schleinitz, R Castellano, J Rey, F Mallet, F Orlanducci, L Pouyet, S Just-Landi, D Coso, V Ivanov, X Carcopino, R Bouabdallah, Y Collette, C Fauriat, D Olive
Journal of Clinical Immunology 2012
Investigation of NK cell function and their modulation in different malignancies
G Konjevic, V Jurisic, V Jovic, A Vuletic, KM Martinovic, S Radenkovic, I Spuzic
Immunologic Research 2012
Natural killer cells in non-hematopoietic malignancies
M Desbois, S Rusakiewicz, C Locher, L Zitvogel, N Chaput
Frontiers in immunology 2012
“Stealth” tumors
E Mamessier, F Bertucci, R Sabatier, D Birnbaum, D Olive
OncoImmunology 2012
Tumor microenvironment in NSCLC suppresses NK cells function
I Cremer, WH Fridman, C Sautès-Fridman
OncoImmunology 2012
How melanoma cells inactivate NK cells
G Pietra, M Vitale, L Moretta, MC Mingari
OncoImmunology 2012
The Immune Microenvironment of Human Tumors: General Significance and Clinical Impact
WH Fridman, MC Dieu-Nosjean, F Pagès, I Cremer, D Damotte, C Sautès-Fridman, J Galon
Cancer Microenvironment 2012
Rapid development of exhaustion and down-regulation of eomesodermin limit the antitumor activity of adoptively transferred murine natural killer cells
S Gill, AE Vasey, AD Souza, J Baker, AT Smith, HE Kohrt, M Florek, KD Gibbs, K Tate, DS Ritchie, RS Negrin
Blood 2012
The immune contexture in human tumours: impact on clinical outcome
WH Fridman, F Pagès, C Sautès-Fridman, J Galon
Nature Reviews Cancer 2012
Biological role of NK cells and immunotherapeutic approaches in breast cancer
MP Roberti, J Mordoh, EM Levy
Frontiers in immunology 2012
Pulmonary surfactant: an immunological perspective
ZC Chroneos, Z Sever-Chroneos, VL Shepherd
Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology 2009

← Previous 1 2 3 … 13 14 Next →

Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Referenced in 2 patents
Highlighted by 1 platforms
481 readers on Mendeley
See more details